Radiotherapy stent

Details Radiotherapy stent Radiotherapy stent

1999-04-20

2001-02-20

Mendez, Manuel (Department: 3734)

Surgery

Means for introducing or removing material from body for...

Infrared, visible light, ultraviolet, x-ray or electrical...

Reexamination Certificate

active

06192271

ABSTRACT:

BACKGROUND OF THE INVENTION
This invention relates to the field of radiotherapy, and more particularly to the field of intra-arterial stents that are used for implanting at or adjacent the side of treatment of cancer cells or other patholitical conditions in a human body.
The intra-arterial stents have been widely used to prevent restenosis following angioplasty, wherein a coronary artery is dilated with a balloon. In time, the artery widened by an implanted balloon tends to close due to elastic recoil of the tissue. In the past, one of the solutions was to use a stent with radiation material embodied into the body of the implant in order to maintain patency of the artery following angioplasty. However, implantation of the stent often leads to intimal hyperplasia in about six months and causes closure of the artery again.
One example of a stent which utilizes a radioisotope imbedded into an arterial stent has been disclosed in U.S. Pat. No. 5,059,166 issued on Oct. 22, 1991 to Fischell et al. In that patent, the stent is implanted at a place in the artery wherein it irradiates a tissue in close proximity to the implantation site of the stent and reduces the tissue growth following a balloon angioplasty. The stent according to '166 patent has a cross section of two turns of a coil spring fabricated from a pure metal or alloy, which has been irradiated to become radioactive. The radioisotope used in '166 patent may be an alpha-beta or gamma emitter. The half life is between 10 hours and 100 days. The most preferable embodiment would have a half life of 16 days.
One of the disadvantages of this type of stent is that it presents a considerable storage problem. The half life of the isotope is very limited, and a surgeon or radiation oncologist has to keep a continuously fresh supply of stents ready for his use during an implantation surgery. Once the isotope has lost its effectiveness, the stent has to be discarded and new stents have to be purchased. Therefore, the physician is required to predict how many stents he would require during a particular period of time and order only the required amount, so as to not waste the valuable devices.
Another example of a radioactive stent is disclosed in U.S. Pat. No. 5,213,561 issued on May 25, 1993. In that patent, the radioactive source is mounted at the distal end of a guide wire, or in a balloon catheter. A balloon expansible stent as is inserted through the vascular structure to the site of radiation treatment. The flexible member is inserted longitudinally through the structure and a radioactive source mounted at the distal end of the flexible member becomes placed at the end of the tube, inside the balloon. An outer sleeve of the guide wire slides over the inner wire for a distance sufficient to cover and uncover radioactive material, so that the shield formed by the outer sleeve can be moved away from the radioactive material and expose the angioplasty site to radiation. After the exposure, the outer sleeve is shifted again to cover the radioactive section. The device is designed to selectively prevent exposure of the walls of the vascular structure when the guide wires are inserted or being removed.
Still another example of a radioactive stent is disclosed in U.S. Pat. No. 5,572,984 issued on Mar. 3, 1998 to Fischell et al. There, a radioactive coating on an embedded radioactive isotope performs both antithrombogenic and radioactive function. The preferred embodiment of '984 patent discloses a phosphorylcholine coated stent where some of the phosphate groups contain phosphorus
32
. Another example of a stent prepared with a radioactive coating is disclosed in U.S. Pat. No. 5,176,617 issued on Jan. 5, 1993 to Fischell et al. In that patent, the stent is a tubular, thin-walled structure that extends radially outward against the wall of the vessel, with a part of the stent being formed from a radioisotope material.
In all these patents, the radioisotope is integral to a stent and is designed to irradiate tissue in close proximity to the implantation site of the stent. Some of the devices are designed to reduce malignant cell growth in a blood vessel, for example a bile duct, while others are designed to maintain vessel patency without injuring the surrounding tissue. All of the above patents suffer from the same disadvantage; they have a limited shelf life, and a supply of them must be continuously replaced in order to provide more benefits to the patient.
The present invention contemplates elimination of drawbacks associated with the prior art and provision of a radiotherapy stent that has a more or less unlimited shelf life and can be loaded with radioactive material immediately prior to positioning in a human body.
SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide a radiotherapy stent suitable for implanting into a blood vessel for delivering radioactive rays to the tissue surrounding the implantation site.
It is another object of the present invention to provide a stent capable of inhibiting intimal hyperplasia of a blood vessel following balloon angioplasty.
It is a further object of the present invention to provide a radiation stent assembly with unlimited shelf life, capable of being assembled immediately prior to implantation.
These and other objects of the present invention are achieved through a provision of a device and method for delivering radioactive energy to a patient=s vascular system. The device of the present invention comprises a stent assembly having a mesh body, at least one hollow sleeve secured to an exterior wall of the mesh body and radioactive member that is loaded into the sleeve immediately prior to inserting of the stent assembly into the blood vessel. The stent assembly can be made with a plurality of sleeves, allowing more radioactive material to be delivered to the treatment site. The mesh body can be delivered to the treatment site by any suitable means, such as a balloon device, a catheter and the like. Once the collapsed stent assembly is delivered to the desired position in the vessel, it is expanded such that the elongated sleeve aligns itself along the wall of the blood vessel, while the assembly lodges against the inner wall of the blood vessel.
The radioactive material contained in the sleeve emits radioactive rays, preventing restenosis of the blood vessel following angioplasty. The same stent device and method can be used for radiotherapy of the patient, where the dose of radiation can be controlled by the amount and strength of the radioactive material loaded into the sleeve.
The radioactive material can be made in the form of small pellets, or balls, or in the form of tiny cylinders that are secured together end-to-end to form a continuos string, or line. The open ends of the sleeve are closed in any desired manner to prevent the radioactive material from escaping the sleeve during and after positioning of the device in the vascular system of a patient.


REFERENCES:
patent: 5891108 (1999-04-01), Leone et al.
patent: 5899882 (1999-05-01), Waksman et al.
patent: 5980566 (1999-11-01), Alt et al.
patent: 6019779 (2000-02-01), Thorud et al.
patent: 6039757 (2000-03-01), Edwards et al.

Affiliated with

Also associated with

Rating

Radiotherapy stent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Radiotherapy stent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiotherapy stent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2589548